Primo Chemicals (PRIMO)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Moderate leverage: Debt/Equity of 0.41, so the balance sheet is not stretched.
• Reasonable asset backing: book value of ₹15.42 versus price of ₹24.29 gives a P/B of 1.58, offering some downside cushion.
• Revenue scale: latest quarter sales of ₹140 Cr against a ₹454 Cr market cap indicates a sizeable operating base.

Concerns

• Earnings collapse: net profit down 69.43%, with latest quarter profit of only ₹1 Cr on ₹140 Cr sales.
• Poor returns: ROE of 1.14% and ROCE of 6.65% are far below what a shareholder should expect.
• Unattractive valuation: P/E of 53.19 with zero dividend yield gives little compensation for cyclical and commodity risks.
• Weak fundamentals: Piotroski F-Score of 3/9 signals deteriorating financial health.

AI Analysis

I've often said it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. Primo Chemicals looks like a fair-to-middling commodity chemical business at a price that offers no Buffett-style bargain. With annual sales declining 2.58%, net profit plunging 69.43%, and the latest quarter delivering just ₹1 Cr profit on ₹140 Cr sales, this is a business earning a very thin margin. ROE of 1.14% and ROCE of 6.65% tell me the capital employed is not earning its keep. In Graham's terms, the margin of safety is missing. Yes, the balance sheet has manageable debt at 0.41 D/E, and book value of ₹15.42 provides some floor; at ₹24.29 you pay 1.58 times book for a company generating negligible returns. A P/E of 53.19 is not an earnings yield that compensates for cyclicality and commodity pricing pressure. The Piotroski F-Score of 3 out of 9 reinforces my caution — financial health is below average. Promoter holding of 32.40% is acceptable but not a signal of high skin in the game. There is no dividend to compensate while waiting. I won't predict the commodity cycle; like a farmer, I know weather is not forecastable. Primo may recover when chemical prices improve, but as investors we are not paid based on tomorrow's hope alone. With profits collapsed and no clear evidence of competitive advantage, this is a cyclical business in a downswing. I'd want a much lower price — perhaps closer to book value — or visible revival in margins before looking seriously. Until then, I watch from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer